RFK Jr. Walks a Tightrope on Trump Deal for Obesity Drugs

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.

News
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.

News
What Trump’s New Drug Pricing Deal Means for People With Obesity

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

News
Trump Announces Deal to Drop Obesity Drug Prices to as Little as $150 a Month

President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.

News
Costco to Sell Ozempic and Wegovy, Weight-Loss Wonder Drugs

Costco members will pay $499 a month out of pocket, the same price offered at CVS and Walmart, and on the manufacturer’s direct-to-consumer website.

News
How Private Equity Oversees the Ethics of Drug Research

Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.

News
Novo Nordisk’s Woes Are Slimming Denmark’s Economic Growth

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too.

News
Targeting Hims & Hers, F.D.A. Takes on a New Type of Drug Advertiser

Regulators sent about 100 warning letters this week to drug advertisers, including to Hims & Hers, a major online provider of weight-loss drugs.

News
Ozempic Maker Novo Nordisk to Cut 9,000 Jobs

The Danish drugmaker said it needed to streamline operations and become more agile, as it faces a more competitive and consumer-focused market.

News
Where U.S. Medicines Are Made and How Trump’s Tariffs Could Affect Them

President Trump’s planned pharmaceutical tariffs threaten to hit many of the most common and well-known drugs that Americans take.

News